J&J’s Novel “Cancer Interception” Strategy: Diagnose Early, Treat Early
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson Pharmaceuticals is adopting a philosophy of "cancer interception" that it believes will go along with a paradigm shift in the way cancers are treated, the firm's head of oncology R&D announced during a day-long business update May 26.
You may also be interested in...
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.